Glycosylation

Glycosylation describes the enzymatic process adding carbohydrate moieties to proteins or lipids, representing the most common and structurally diverse post-translational modification critically affecting protein properties, cellular recognition, and biological functions. This complex biosynthetic pathway occurs primarily in endoplasmic reticulum and Golgi apparatus, creating microheterogeneity in glycoprotein populations even from single cell lines.

The biopharmaceutical industry carefully manages glycosylation throughout therapeutic protein development and manufacturing. Monoclonal antibody glycosylation influences effector functions, with afucosylation enhancing antibody-dependent cellular cytotoxicity and sialylation reducing immunogenicity. Manufacturing process development optimises culture conditions including pH, temperature, dissolved oxygen, and feeding strategies controlling glycosylation profiles. Analytical characterisation employs orthogonal techniques comprehensively profiling glycosylation including site occupancy, glycan structures, and relative abundances. Glycosylation serves as key comparability indicator following manufacturing changes or demonstrating biosimilar similarity. As analytical capabilities improve, glycosylation control becomes increasingly sophisticated enabling optimisation of therapeutic properties.